The Tokyo-based biotech firm expects RV-001 to be able to alter light sensitivity for patients with limited or no vision regardless of genotype.

TOKYO -- Japanese researchers from Keio University and elsewhere announced Thursday that they have begun a clinical trial on a gene therapy to restore light sensitivity in patients with retinitis ...

Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been ...

Motorists risk being hit with an eye-watering £1,000 fine if they fail to declare certain conditions to the DVLA ...

In this Healio Video Perspective from Retina 2025, Allen C. Ho, MD, discusses the growing promise of optogenetic therapy in treating patients with retinal disease.

Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of its gene-agnostic therapy, OCU400, as the European Commission has delivered a positive opinion designating it ...

(RTTNews) - Ocugen, Inc. (OCGN) Monday said that the European Medicines Agency's (EMA) Committee for Advanced Therapies (CAT) has provided a positive opinion for Advanced Therapy Medicinal Product ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds were identified using a virtual screening approach.

Apple's Vision Pro headset offers access to plenty of software. We pick the top 31 apps on visionOS, from movies and games to videoconferencing and...ordering cookies. I’ve been PCMag’s home ...

THE loss of dark adaptation and night blindness which characterizes the earliest stages of retinitis pigmentosa suggested to us the possibility that one of the fundamental features of the ...

At its Unpacked event, Samsung showed off its upcoming "Project Moohan" AR/VR headset, which is designed to compete with the Vision Pro. Some users might even mistake the headset for a Vision Pro ...